8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 12, 2026·SEC
Dianthus Therapeutics, Inc.(DNTH)Earnings, Financials & Key Ratios
DNTH•NASDAQ
Price updated Jun 11, 2026
AboutDianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.Show more
- Revenue$2M-67.3%
- EBITDA-$178M-75.4%
- Net Income-$162M-91.1%
- EPS (Diluted)-4.20-64.7%
- Gross Margin100%
- EBITDA Margin-8739.34%-437.1%
- Operating Margin-8739.34%-434.9%
- Net Margin-7973.33%-485.1%
- ROE-38.38%-17.8%
- ROIC-34.44%+17.0%
- Debt/Equity0.00-33.6%
DNTH Key Insights
Dianthus Therapeutics, Inc. (DNTH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Profits declining 16.7% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 13.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DNTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DNTH Price & Volume
Dianthus Therapeutics, Inc. (DNTH) stock price & volume — 10-year historical chart
Loading chart...
DNTH Growth Metrics
Dianthus Therapeutics, Inc. (DNTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-31.8%
TTM-79.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM88.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM96.18%
Return on Capital
10 Years-54.4%
5 Years-30.22%
3 Years-39.92%
Last Year-41.59%
DNTH Recent Earnings
Dianthus Therapeutics, Inc. (DNTH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (73%)
Q2 2026Latest
May 5, 2026EPS
$0.85
Est $1.17
+27.4%
Revenue
$463,000
Est $403,615
+14.7%
Q2 2026
Mar 9, 2026EPS
$1.43
Est $0.98
-45.9%
Revenue
$284,000
Est $552,231
-48.6%
Q4 2025
Nov 5, 2025EPS
$0.97
Est $0.86
-12.8%
Revenue
$396,000
Est $398,090
-0.5%
Q3 2025
Aug 7, 2025EPS
$0.88
Est $0.86
-2.3%
Revenue
$193,000
Est $864,670
-77.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.85vs $1.17+27.4% | $463,000vs $403,615+14.7% |
| Q2 2026 | Mar 9, 2026 | $1.43vs $0.98-45.9% | $284,000vs $552,231-48.6% |
| Q4 2025 | Nov 5, 2025 | $0.97vs $0.86-12.8% | $396,000vs $398,090-0.5% |
| Q3 2025 | Aug 7, 2025 | $0.88vs $0.86-2.3% | $193,000vs $864,670-77.7% |
Based on last 12 quarters of dataView full earnings history →
DNTH Peer Comparison
Dianthus Therapeutics, Inc. (DNTH) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALXO | 82.43M | 1.52 | -0.80 | -124.06% | 0.20 | |||
 BCAB | 4.49M | 3.56 | -0.07 | -81.82% | -25.31% | |||
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 | |
 APLS | 5.25B | 41.03 | 227.94 | 28.46% | 12.95% | 39.71% | 1.31 | |
 OMAB | 4.79B | 99.20 | 15.60 | 5.91% | 33.46% | 50.64% | 1.19 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 VKTX | 3.32B | 28.61 | -8.97 | -71.31% | 0.00 |
Compare DNTH vs Peers
Dianthus Therapeutics, Inc. (DNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DNTH Income Statement
Dianthus Therapeutics, Inc. (DNTH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M | 1.34M |
Revenue Growth % | - | - | - | - | - | 334.76% | -55.96% | 120.63% | -67.35% | -79.52% |
Cost of Goods Sold | 376K | 875K | 1.84M | 1.98M | 0 | 0 | 0 | 0 | 0 | 76K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -376K▲ 0% | -875K▼ 132.7% | -1.84M▼ 110.6% | -1.98M▼ 7.3% | 1.48M▲ 174.6% | 6.42M▲ 334.8% | 2.83M▼ 56.0% | 6.24M▲ 120.6% | 2.04M▼ 67.3% | 1.26M▲ 0% |
Gross Margin % | - | - | - | - | 100% | 100% | 100% | 100% | 100% | 94.31% |
Gross Profit Growth % | -6166.67% | -132.71% | -110.63% | -7.32% | 174.62% | 334.76% | -55.96% | 120.63% | -67.35% | - |
Operating Expenses | 35.35M | 59.09M | 81.13M | 76.72M | 14.56M | 36.12M | 51M | 108.1M | 179.97M | 192.55M |
OpEx % of Revenue | - | - | - | - | 986.59% | 562.91% | 1804.67% | 1733.75% | 8839.34% | - |
Selling, General & Admin | 7.45M | 17.75M | 23.76M | 28.09M | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M | 39.46M |
SG&A % of Revenue | - | - | - | - | 132.52% | 105.08% | 642.57% | 400.87% | 1686.2% | - |
Research & Development | 27.9M | 41.34M | 57.37M | 48.64M | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M | 153.16M |
R&D % of Revenue | - | - | - | - | 854.06% | 457.83% | 1162.1% | 1332.88% | 7153.14% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -35.73M▲ 0% | -59.96M▼ 67.8% | -82.97M▼ 38.4% | -78.7M▲ 5.1% | -13.09M▲ 83.4% | -29.7M▼ 127.0% | -48.17M▼ 62.2% | -101.86M▼ 111.5% | -177.93M▼ 74.7% | -191.29M▲ 0% |
Operating Margin % | - | - | - | - | -886.59% | -462.91% | -1704.67% | -1633.75% | -8739.34% | -14318.04% |
Operating Income Growth % | -285.49% | -67.84% | -38.37% | 5.14% | 83.37% | -127% | -62.17% | -111.45% | -74.68% | - |
EBITDA | -35.35M | -59.09M | -81.13M | -76.72M | -13.09M | -29.56M | -47.82M | -101.45M | -177.93M | -190.83M |
EBITDA Margin % | - | - | - | - | -886.59% | -460.62% | -1692.11% | -1627.14% | -8739.34% | -14283.53% |
EBITDA Growth % | -281.68% | -67.15% | -37.3% | 5.43% | 82.94% | -125.88% | -61.78% | -112.16% | -75.39% | -63.44% |
D&A (Non-Cash Add-back) | 376K | 875K | 1.84M | 1.98M | 0 | 147K | 355K | 412K | 0 | 461K |
EBIT | -35.49M | -57.52M | -76.77M | -74.94M | -13.09M | -29.7M | -48.17M | -101.86M | -177.93M | -187.77M |
Net Interest Income | 0 | 0 | 0 | 0 | 100K | 1.15M | 4.76M | 17.36M | 16.12M | 18.59M |
Interest Income | 236K | 2.45M | 0 | 3.77M | 100K | 1.15M | 4.76M | 17.36M | 16.12M | 18.59M |
Interest Expense | 0 | 0 | 0 | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 236K | 2.45M | 6.2M | 3.77M | -23K | 1.23M | 4.62M | 16.89M | 15.6M | 179.97M |
Pretax Income | -35.49M▲ 0% | -57.52M▼ 62.1% | -76.77M▼ 33.5% | -74.94M▲ 2.4% | -13.11M▲ 82.5% | -28.48M▼ 117.2% | -43.55M▼ 53.0% | -84.97M▼ 95.1% | -162.34M▼ 91.1% | -11.32M▲ 0% |
Pretax Margin % | - | - | - | - | -888.14% | -443.76% | -1541.22% | -1362.77% | -7973.33% | -847.53% |
Income Tax | 236K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.66% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -35.49M▲ 0% | -57.52M▼ 62.1% | -76.77M▼ 33.5% | -74.94M▲ 2.4% | -13.11M▲ 82.5% | -28.48M▼ 117.2% | -43.55M▼ 53.0% | -84.97M▼ 95.1% | -162.34M▼ 91.1% | -11.32M▲ 0% |
Net Margin % | - | - | - | - | -888.14% | -443.76% | -1541.22% | -1362.77% | -7973.33% | -847.53% |
Net Income Growth % | -276.32% | -62.06% | -33.48% | 2.39% | 82.51% | -117.22% | -52.95% | -95.08% | -91.05% | 88.76% |
Net Income (Continuing) | -35.49M | -57.52M | -76.77M | -74.94M | -13.11M | -28.48M | -43.55M | -84.97M | -162.34M | -11.32M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -16.05▲ 0% | -27.62▼ 72.1% | -33.18▼ 20.1% | -27.30▲ 17.7% | -3.82▲ 86.0% | -7.60▼ 99.0% | -8.45▼ 11.2% | -2.55▲ 69.8% | -4.20▼ 64.7% | -0.24▲ 0% |
EPS Growth % | -275.88% | -72.09% | -20.13% | 17.72% | 86.01% | -98.95% | -11.18% | 69.82% | -64.71% | 96.18% |
EPS (Basic) | -16.05 | -27.62 | -33.18 | -27.30 | -3.82 | -7.60 | -8.45 | -2.55 | -4.20 | - |
Diluted Shares Outstanding | 2.21M | 2.08M | 2.31M | 2.75M | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M | 48.03M |
Basic Shares Outstanding | 2.21M | 2.08M | 2.31M | 2.75M | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M | 48.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DNTH Balance Sheet
Dianthus Therapeutics, Inc. (DNTH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 52.5M | 145.32M | 149.84M | 151.53M | 180.69M | 82.03M | 177.45M | 280.9M | 409.44M | 1.12B |
Cash & Short-Term Investments | 51.57M | 142.57M | 145.73M | 148.84M | 176.93M | 75.49M | 173.72M | 275.24M | 404.3M | 1.11B |
Cash Only | 51.57M | 58.34M | 65.07M | 58.15M | 131.65M | 15.37M | 132.32M | 22.79M | 51.09M | 627.67M |
Short-Term Investments | 0 | 84.22M | 80.66M | 90.68M | 45.28M | 60.13M | 41.39M | 252.45M | 353.21M | 483.59M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 5.64M | 478K | 807K | 102K | 1.31M |
Days Sales Outstanding | - | - | - | - | - | 320.69 | 61.74 | 47.24 | 18.29 | 440.81 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 936K | 2.75M | 4.11M | 2.69M | 3.77M | 53K | 504K | 355K | 5.04M | 0 |
Total Non-Current Assets | 1.96M | 11.99M | 11.67M | 10.09M | 9.24M | 1.08M | 1.95M | 93.1M | 121.48M | 126.97M |
Property, Plant & Equipment | 1.74M | 3.07M | 9.89M | 8.31M | 7.46M | 956K | 800K | 1.75M | 1.63M | 1.57M |
Fixed Asset Turnover | - | - | - | - | 0.20x | 6.71x | 3.53x | 3.57x | 1.25x | 0.85x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 218K | 8.92M | 1.78M | 1.78M | 1.78M | 0 | 0 | 81.73M | 110.14M | 428.58M |
Other Non-Current Assets | 4K | 0 | 0 | 0 | 0 | 121K | 1.15M | 9.63M | 9.72M | 11.54M |
Total Assets | 54.46M▲ 0% | 157.31M▲ 188.8% | 161.51M▲ 2.7% | 161.62M▲ 0.1% | 189.93M▲ 17.5% | 83.11M▼ 56.2% | 179.41M▲ 115.9% | 374.01M▲ 108.5% | 530.92M▲ 42.0% | 1.25B▲ 0% |
Asset Turnover | - | - | - | - | 0.01x | 0.08x | 0.02x | 0.02x | 0.00x | 0.00x |
Asset Growth % | 380.19% | 188.84% | 2.67% | 0.07% | 17.52% | -56.24% | 115.86% | 108.47% | 41.95% | 351.04% |
Total Current Liabilities | 4.14M | 10.42M | 14.12M | 11.43M | 10.86M | 8.22M | 9.63M | 18.45M | 30.73M | 38.28M |
Accounts Payable | 167K | 3.49M | 2.81M | 3.76M | 3.04M | 1.17M | 2.61M | 4.58M | 9.72M | 5.27M |
Days Payables Outstanding | 162.11 | 1.46K | 556.91 | 693.83 | - | - | - | - | - | 32.55K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 320K | 367K | 399K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 100K | 100K | 479K | 1.19M | 4.11M |
Other Current Liabilities | 2.65M | 4.4M | 8.06M | 4.56M | 4.48M | 2.08M | 5.36M | 13.07M | 19.45M | 31.13M |
Current Ratio | 12.68x | 13.95x | 10.62x | 13.26x | 16.63x | 9.97x | 18.42x | 15.22x | 13.32x | 29.25x |
Quick Ratio | 12.68x | 13.95x | 10.62x | 13.26x | 16.63x | 9.97x | 18.42x | 15.22x | 13.32x | 29.25x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -32.11K |
Total Non-Current Liabilities | 0 | 1.25M | 6.21M | 6.28M | 6.4M | 1.23M | 904K | 3.08M | 6.79M | 7.29M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M | 965K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 438K | 168K | 1.17M | 0 | 1.12M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1.25M | 6.21M | 6.28M | 6.4M | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4.14M | 11.66M | 20.32M | 17.71M | 17.26M | 9.45M | 10.54M | 21.53M | 37.52M | 45.57M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 788K | 585K | 1.49M | 1.39M | 1.36M |
Net Debt | -51.57M | -58.34M | -65.07M | -58.15M | -131.65M | -14.58M | -131.74M | -21.3M | -49.7M | -626.3M |
Debt / Equity | - | - | - | - | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 3.28x |
Interest Coverage | - | - | - | -19.90x | - | - | - | - | - | - |
Total Equity | 50.32M▲ 0% | 145.65M▲ 189.4% | 141.19M▼ 3.1% | 143.91M▲ 1.9% | 172.67M▲ 20.0% | 73.66M▼ 57.3% | 168.87M▲ 129.3% | 352.48M▲ 108.7% | 493.4M▲ 40.0% | 1.2B▲ 0% |
Equity Growth % | 456.53% | 189.44% | -3.06% | 1.92% | 19.99% | -57.34% | 129.27% | 108.73% | 39.98% | 351.89% |
Book Value per Share | 22.76 | 69.95 | 61.03 | 52.42 | 50.28 | 19.66 | 32.77 | 10.58 | 13.05 | 25.01 |
Total Shareholders' Equity | 50.32M | 145.65M | 141.19M | 143.91M | 172.67M | 73.66M | 168.87M | 352.48M | 493.4M | 1.2B |
Common Stock | 6K | 33K | 39K | 49K | 59K | 0 | 15K | 31K | 43K | 54K |
Retained Earnings | -45.21M | -102.73M | -179.5M | -254.43M | -325.57M | -45.87M | -89.42M | -174.39M | -336.73M | -377.56M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -382K | -8K | 8K | -23K | -30K | -161K | 47K | 106K | 489K | -575K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DNTH Cash Flow Statement
Dianthus Therapeutics, Inc. (DNTH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -22.26M | -41.89M | -57.1M | -64.02M | -59.53M | -29.07M | -36.86M | -78.18M | -129.06M | -130.29M |
Operating CF Margin % | - | - | - | - | -4033.27% | -453.02% | -1304.35% | -1253.89% | -6338.9% | - |
Operating CF Growth % | -240.99% | -88.14% | -36.33% | -12.12% | 7.02% | 51.17% | -26.8% | -112.09% | -65.08% | -183.76% |
Net Income | -35.49M | -57.52M | -76.77M | -74.94M | -71.14M | -28.48M | -43.55M | -84.97M | -162.34M | -11.32M |
Depreciation & Amortization | 376K | 875K | 1.84M | 1.98M | 2.02M | 147K | 355K | 412K | 428K | 371K |
Stock-Based Compensation | 2.26M | 0 | 0 | 0 | 0 | 1.52M | 2.9M | 12.89M | 22.79M | 28.08M |
Deferred Taxes | 0 | 0 | -13.54M | -12.95M | 0 | 0 | -661K | 0 | 0 | 0 |
Other Non-Cash Items | 13.41M | 10.02M | 22.53M | 23.07M | 11.11M | -606K | -762K | -6.17M | -6.67M | -5.68M |
Working Capital Changes | 1.32M | 3.98M | 8.83M | -1.19M | -1.53M | -1.65M | 4.86M | -351K | 16.73M | 20.61M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -4.16M | 5.16M | 0 | 755K | -230K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.13M | 2.5M | 145K | 948K | -720K | 2.28M | 661K | 8.19M | 11.28M | 19.78M |
Cash from Investing | -2.2M | -91.7M | 1.53M | -10.63M | 43.43M | -59.82M | 20.25M | -286.81M | -122.83M | -271.6M |
Capital Expenditures | -2.2M | -7.67M | -3.06M | -400K | -1.26M | -139K | -110K | -105K | -213K | -199K |
CapEx % of Revenue | - | - | - | - | 85.64% | 2.17% | 3.89% | 1.68% | 10.46% | 14.9% |
Acquisitions | 0 | 12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -135K | 12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 71.49M | 142.15M | 62.3M | 67.74M | 89.6M | 96.68M | 133.57M | 255.62M | 280.13M | 1.02B |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 71.49M | 142.15M | 62.3M | 67.74M | 89.6M | 100M | 72M | 269.2M | 280.13M | 739.25M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -213K | -88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 317K |
Other Financing | 0 | 0 | 0 | 0 | 0 | -3.32M | 61.57M | -13.57M | 0 | 280.13M |
Net Change in Cash | 47.02M▲ 0% | 6.78M▼ 85.6% | 6.73M▼ 0.8% | -6.92M▼ 202.9% | 73.5M▲ 1162.3% | 7.79M▼ 89.4% | 116.97M▲ 1402.1% | -109.37M▼ 193.5% | 28.23M▲ 125.8% | 617.49M▲ 0% |
Free Cash Flow | -24.46M▲ 0% | -49.56M▼ 102.6% | -60.16M▼ 21.4% | -64.42M▼ 7.1% | -60.8M▲ 5.6% | -29.21M▲ 52.0% | -36.97M▼ 26.6% | -78.28M▼ 111.7% | -129.27M▼ 65.1% | -130.49M▲ 0% |
FCF Margin % | - | - | - | - | -4118.9% | -455.18% | -1308.24% | -1255.57% | -6349.36% | -9766.84% |
FCF Growth % | -266.86% | -102.59% | -21.4% | -7.08% | 5.63% | 51.95% | -26.57% | -111.75% | -65.13% | -43.44% |
FCF per Share | -11.07 | -23.80 | -26.01 | -23.47 | -17.70 | -7.79 | -7.17 | -2.35 | -3.42 | -2.72 |
FCF Conversion (FCF/Net Income) | 0.63x | 0.73x | 0.74x | 0.85x | 4.54x | 1.02x | 0.85x | 0.92x | 0.80x | 11.52x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DNTH Key Ratios
Dianthus Therapeutics, Inc. (DNTH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -119.57% | -58.7% | -53.53% | -52.57% | -8.28% | -23.12% | -35.92% | -32.6% | -38.38% | -1.78% |
| Return on Invested Capital (ROIC) | -1647.42% | -104.52% | -76.15% | -72.93% | -15.48% | -44.51% | -75.11% | -41.49% | -34.44% | -31.85% |
| Gross Margin | - | - | - | - | 100% | 100% | 100% | 100% | 100% | 94.31% |
| Net Margin | - | - | - | - | -888.14% | -443.76% | -1541.22% | -1362.77% | -7973.33% | -847.53% |
| Debt / Equity | - | - | - | - | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | - | - | - | -19.90x | - | - | - | - | - | - |
| FCF Conversion | 0.63x | 0.73x | 0.74x | 0.85x | 4.54x | 1.02x | 0.85x | 0.92x | 0.80x | 11.52x |
| Revenue Growth | - | - | - | - | - | 334.76% | -55.96% | 120.63% | -67.35% | -79.52% |
Related:DNTH Dividend History·DNTH Revenue History·DNTH Price History·DNTH P/E History·DNTH Financial Ratios·DNTH Institutional Holders
DNTH SEC Filings & Documents
Dianthus Therapeutics, Inc. (DNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
DNTH Frequently Asked Questions
Dianthus Therapeutics, Inc. (DNTH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Dianthus Therapeutics, Inc. (DNTH) reported $1.3M in revenue for fiscal year 2025.
Dianthus Therapeutics, Inc. (DNTH) saw revenue decline by 67.3% over the past year.
Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $11.3M for fiscal year 2025.
Dividend & Returns
Dianthus Therapeutics, Inc. (DNTH) has a return on equity (ROE) of -38.4%. Negative ROE indicates the company is unprofitable.
Dianthus Therapeutics, Inc. (DNTH) had negative free cash flow of $130.5M in fiscal year 2025, likely due to heavy capital investments.